Europe Vaccine Adjuvant Market

Europe Vaccine Adjuvant Market Size 

The Europe Vaccine Adjuvant Market is projected to grow from USD 187.85 million in 2025 to USD 207.57 million in 2026 and reach USD 463.27 million by 2034, registering a CAGR of 10.55% during the forecast period from 2026 to 2034.

A vaccine adjuvant is an agent that helps to produce more antibodies and create longer-lasting immunity. The increasing of patients with infectious diseases and cancer in the region drives the European vaccine market. Recently, the coronavirus outbreak has helped the European vaccine adjuvant market as it is an infectious disease. Also, the developed technology of Germany and Italy is helping the addition of innovative vaccine adjuvants for flu diseases. The high prevalence of HIV and Coronavirus disease is driving the growth of the European vaccine adjuvant market. The government and NGOs have funding for clinical trials for the new adjuvant vaccine discovery to boost immunity during this pandemic.

However, side effects and high costs of treatment associated with the vaccine adjuvants hamper the market's growth to some extent. In addition, the advanced and recent molecular antigen technologies will need a highly competent and powerful adjuvant vaccine for immunization, which is a big challenge for the adjuvant vaccine market. As per the European authority, the adjuvant cannot get approval without vaccines, and the lack of universities due to safety is a hurdle for this European market.

REGIONAL ANALYSIS

Regionally, Germany and the U.K. are expected to experience robust growth in the forecast period due to increasing regional awareness.

Italy has created tremendous demand for the newly developed adjuvant vaccine due to the high number of Coronavirus patients affected in this country. The government has taken the initiative to boost patients' immunity, and Developed healthcare is the factor that helps the growth of the vaccine adjuvants market in Italy. In addition, the high prevalence of Influenza is more in geriatric patients, and more than 10% of the aged population in Italy are factors driving the market's growth.

The German vaccine adjuvant market is expected to grow at a robust CAGR during the forecast period due to the rising geriatric population and swine flu patients. Furthermore, in 2020, the department of vaccinology and microbiology Germany developed a new adjuvant vaccine combination with an enhanced immune response for particular antigens and antibodies to reduce the limitation of vaccine adjuvants in the market.

UK researchers have to work during this COVID-19 pandemic to launch a new adjuvant vaccine, generating the strongest, most capable, and most durable immune response to combat the SARS-COV-2 virus. The presence of prominent players in the UK to develop vaccine adjuvants helps boost the UK vaccine adjuvant market.

Currently, the high prevalence of hepatitis B, Influenza, and more demand for the aluminum adjuvant in France are fuelling the market's growth.

KEY MARKET PLAYERS

Companies playing a prominent role in the European vaccine adjuvant market profiled in this report are MPV Technologies, Avanti Polar Lipids, Novavax Inc. Brenntag Biosector, SEPPIC, Agenus, Inc., Invivogen, SPI Pharma, Inc., CSL Limited, and OZ Biosciences.

MARKET SEGMENTATION

This research report on the European vaccine adjuvant market has been segmented and sub-segmented into the following categories

By Type 

• Aluminum Salts
• Tensoactive Adjuvants
• Adjuvant Emulsions
• Bacteria Derived Adjuvants
• Liposome Adjuvants
• Carbohydrate Adjuvants

By Route Of Administration 

• Oral
• Intradermal
• Subcutaneous
• Intranasal
• Intramuscular

By Mechanism Of Action 

• Immune Stimulants
• Carriers
• Vehicle Adjuvants

By Country 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe